Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime

Cefotaxime is the most commonly used antibiotic for initial therapy of spontaneous bacterial peritonitis in cirrhosis. However, since the introduction of cefotaxime no study has been performed to investigate factors influencing prognosis in cirrhotic patients with this type of infection. In this study, predictive factors for infection resolution and patient survival were investigated in 213 consecutive episodes of spontaneous bacterial peritonitis in 185 cirrhotic patients. All patients were initially treated with cefotaxime. One hundred sixty‐five episodes (77%) resolved with cefotaxime alone, and two more episodes (1%), initially unresponsive to cefotaxime, were cured after modification of antibiotic therapy. In a multivariate analysis (stepwise logistic regression), only 4 of 51 clinical and laboratory variables obtained at the time of diagnosis of infection were identified as independent predictors of infection resolution: band neutrophils in white blood cell count, community‐acquired vs. hospitalacquired peritonitis, blood urea nitrogen level and serum aspartate aminotransferase level. No patient experienced serious adverse effects related to cefotaxime. Eighty‐two patients died during hospitalization (38% mortality rate in relation to the 213 episodes of peritonitis). In the multivariate analysis, six variables were independently correlated with survival: blood urea nitrogen level, serum aspartate aminotransferase level, community‐acquired vs. hospitalacquired peritonitis, age, Child‐Pugh score and ileus. No microbiological data had predictive value for infection resolution or survival. These results indicate that in cirrhotic patients with spontaneous bacterial peritonitis treated with cefotaxime, infection resolution and patient survival may be predicted by several clinical and laboratory variables obtained at the time of infection diagnosis; the most important are blood urea nitrogen level, serum aspartate aminotransferase level and site (community or hospital) of peritonitis acquisition. (HEPATOLOGY 1993;17:251–257.)

[1]  J. Ariza,et al.  Aztreonam vs. cefotaxime in the treatment of gram‐negative spontaneous peritonitis in cirrhotic patients , 1991, Hepatology.

[2]  J. McHutchison,et al.  Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. , 1991, Gastroenterology.

[3]  G. Kanel,et al.  A rodent model of cirrhosis, ascites, and bacterial peritonitis. , 1991, Gastroenterology.

[4]  J. Such,et al.  Selective intestinal decontamination prevents spontaneous bacterial peritonitis. , 1991, Gastroenterology.

[5]  J. Llach,et al.  Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double‐blind, placebo‐controlled trial , 1990, Hepatology.

[6]  D. Salmon,et al.  Culture-negative neutrocytic ascites: a less severe variant of spontaneous bacterial peritonitis. , 1990, Journal of hepatology.

[7]  F. Pessione,et al.  [Prognosis of spontaneous ascitic infection in cirrhotic patients]. , 1989, Gastroenterologie clinique et biologique.

[8]  B. Runyon.  Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis , 1988, Hepatology.

[9]  J. Llach,et al.  Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. , 1988, Gastroenterology.

[10]  J. Llach,et al.  Recurrence of spontaneous bacterial peritonitis in cirrhosis: Frequency and predictive factors , 1988, Hepatology.

[11]  T. Almdal,et al.  Spontaneous bacterial peritonitis in cirrhosis. Incidence, diagnosis, and prognosis. , 1987, Scandinavian journal of gastroenterology.

[12]  B. Runyon.  Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. , 1986, Gastroenterology.

[13]  J. Hoefs,et al.  Spontaneous Bacterial Peritonitis , 2007, Disease-a-month : DM.

[14]  V. Arroyo,et al.  Cefotaxime is more effective than is ampicillin‐tobramycin in cirrhotics with severe infections , 1985, Hepatology.

[15]  V. Arroyo,et al.  Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage , 1985, Hepatology.

[16]  J. Hoefs,et al.  Culture‐Negative Neutrocytic Ascites: A Variant of Spontaneous Bacterial Peritonitis , 1984, Hepatology.

[17]  G. Drusano,et al.  Integration of selected pharmacologic and microbiologic properties of three new beta-lactam antibiotics: a hypothesis for rational comparison. , 1984, Reviews of infectious diseases.

[18]  V. Arroyo,et al.  Reticuloendothelial System Phagocytic Activity in Cirrhosis and Its Relation to Bacterial Infections and Prognosis , 1984, Hepatology.

[19]  V. Arroyo,et al.  Aminoglycoside nephrotoxicity in cirrhosis: Value of urinary β2-microglobulin to discriminate functional renal failure from acute tubular damage , 1982 .

[20]  J. Fillastre,et al.  Cefaclor pharmacokinetics and renal impairment. , 1980, The Journal of antimicrobial chemotherapy.

[21]  J. Fillastre,et al.  Pharmacokinetics of cefotaxime in subjects with normal and impaired renal function. , 1980, The Journal of antimicrobial chemotherapy.

[22]  C. Stratton,et al.  Spontaneous bacterial peritonitis. A review of 28 cases with emphasis on improved survival and factors influencing prognosis. , 1978, The American journal of medicine.